

Applicant(s): Lord et al.			VN29
Serial No. 10/070,005	Filing Date July 2, 2002	Examiner Jyothsna A. Venkat	Group Art Unit 1615

Invention: SCAR TREATMENT COMPOSITION

OFFICIAL

I hereby certify that this AMENDMENT & REPLY - 37 CFR 1.111  
(Identify type of correspondence)  
is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306)  
on APRIL 28, 2004  
(Date)

KELLY J. SMITH  
(Typed or Printed Name of Person Signing Certificate)  
Kelly J. Smith  
(Signature)

Note: Each paper must have its own certificate of mailing.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) \$86.00

## Complete if Known

Application Number 10/070,005  
Filing Date 07/02/2002  
First Named Inventor Gary Lord  
Examiner Name Jyotsna A. Venkat  
Art Unit 1615  
Attorney Docket No. VN29

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number 04-1520  
Deposit Account Name Dow Corning Corporation

The Director is authorized to:

(check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	2001	770	385	Utility filing fee	
1002	2002	340	170	Design filing fee	
1003	2003	530	265	Plant filing fee	
1004	2004	770	385	Reissue filing fee	
1005	2005	180	80	Provisional filing fee	
SUBTOTAL (1)					(\$)

### 2. EXTRA CLAIM FEES FOR UTILITY AND

Total Claims	Extra Claims	Fee from below	Fee Paid
13	-20** = 0	X 18.00 = 0.00	
Independent Claims	4 - 3** = 1	X 86.00 = 86.00	
Multiple Dependent		0.00 = 0.00	

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
1202	2202	18	8	Claims in excess of 20	
1201	2201	86	43	Independent claims in excess of 3	
1203	2203	290	146	Multiple dependent claim, if not paid	
1204	2204	86	43	** Reissue independent claims over original patent	
1205	2205	18	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					(\$)

\*\*or number previously paid, if greater. For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	2051	130	65	Surcharge - late filing fee or oath	
1052	2052	50	25	Surcharge - late provisional filing fee or cover sheet	
1053	2053	130	130	Non - English specification	
1812	2520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	2251	110	55	Extension for reply within first month	
1252	2252	420	210	Extension for reply within second month	
1253	2253	950	475	Extension for reply within third month	
1254	2254	1,480	740	Extension for reply within fourth month	
1255	2255	2,010	1,005	Extension for reply within fifth month	
1401	2401	330	165	Notice of Appeal	
1402	2402	330	165	Filing a brief in support of an appeal	
1403	2403	290	145	Request for oral hearing	
1451	2451	1,510	1,510	Petition to institute a public use proceeding	
1452	2452	110	55	Petition to revive - unavoidable	
1453	2453	1,330	665	Petition to revive - unintentional	
1501	2501	1,330	665	Utility issue fee (or reissue)	
1502	2502	480	240	Design issue fee	
1503	2503	640	320	Plant issue fee	
1480	2480	130	130	Petitions to the Commissioner	
1807	2807	50	50	Processing fee under 37 CFR § 1.17(q)	
1808	2808	180	180	Submission of Information Disclosure Statement	
8021	28021	40	40	Recording each patent assignment per property (times number of properties)	
1809	2809	770	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	2810	770	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	2801	770	385	Request for Continued Examination (RCE)	
1802	2802	900	900	Request for expedited examination of a design application	
Other fee (specify)					
SUBTOTAL (3)					(\$)

\*Reduced by Basic Filing Fee Paid

## SUBMITTED BY

Name (Print/Type) James L. DeCesare  
Signature

Registration No. (Attorney/Agent)

27,979

## Complete (if applicable)

Telephone

(989) 496-4235

Date

4-28-04

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of ) Group Art Unit 1615  
Gary Lord, Marie T. Valencia & Xavier Thomas ) Examiner Jyothsna A. Venkat  
Serial No. 10/070,005 )  
Filed July 2, 2002 )  
Title Scar Treatment Composition )  
Docket No. VN 29 ) April 27, 2004

OFFICIAL

*AMENDMENT & REPLY - 37 CFR 1.111*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Section a.) Introductory Comments.

This is in response to the Patent Office Action dated February 26, 2004. Please amend the above-identified patent application as indicated in section b.) Amendments to the Claims, shown below starting on separate sheets.

Section b.) Amendments to the Claims.

The text of all claims under examination is shown below in the listing. Claims being amended in this paper include markings indicating changes that have been made relative to the prior version. These changes are shown by strikethrough for deleted matter and underlining for added matter. No accompanying clean version is supplied. The text of pending claims not being currently amended that are under examination are shown in clean version in the listing. Cancelled claims are indicated merely by their status without the text.